GLP-1s: 2024 Clinical Insights An Update On Payer Strategies, New Indications & Drugs In The Pipeline
A must-read for payers, employers & benefit consultants on the future of weight loss drugs
In 2023, weight loss drugs captured the public’s attention like never before, with GLP-1 agonists such as Ozempic, Wegovy, Saxenda and Mounjaro leading the conversation.
Beyond their weight loss benefits, this class of drugs has recently begun to make waves for new cardiac indications, broadening their potential impact on public health and payer budgets.
Our latest guide provides critical clinical updates on:
New players in the weight loss medication space
Insights and payer trends: will coverage expand in 2024?
The long-term impact and costs of GLP-1 weight loss therapies, and more!
Please note: This is an update to our 2023 guide, “Balancing the Scales: A Comprehensive Guide for Healthcare Payers on the Value and Viability of New Weight Loss Medications”
